Emerging Therapies Using Host-Directed Antiviral Strategies for Severe Febrile Infections

Abstract

Severe febrile infections, often caused by highly pathogenic viruses, continue to present significant challenges in clinical management due to limited specific antiviral options and rising drug resistance. Host-directed antiviral strategies represent a paradigm shift, focusing on modulating host cellular pathways to enhance viral clearance, reduce immunopathology, and improve clinical outcomes. This review synthesizes current evidence on the rationale, mechanisms, and clinical potential of host-directed therapies for severe febrile viral infections, highlighting recent advances, ongoing clinical trials, and practical implications for healthcare professionals managing these complex cases.

Introduction

The management of severe febrile infections, such as those caused by influenza, dengue, Ebola, and emerging coronaviruses, remains a pressing concern for clinicians worldwide. Traditional antiviral treatments target viral components directly, but the emergence of resistant strains and the broad diversity of pathogenic viruses underscore the need for novel therapeutic approaches. Host-directed therapies (HDTs) have gained prominence as a means to modulate host responses, potentially offering broad-spectrum efficacy and mitigating the development of resistance. This article provides an evidence-based overview of host-directed antiviral strategies, with emphasis on their clinical relevance, mechanisms of action, and potential role in future therapeutic landscapes.

Epidemiology / Disease Burden

Severe febrile infections are responsible for substantial morbidity and mortality globally, particularly in low- and middle-income countries where viral epidemics are frequent. According to recent World Health Organization data, viral febrile illnesses account for a significant proportion of hospital admissions and intensive care utilization. Epidemics of influenza, dengue, and other emerging viral pathogens regularly strain healthcare systems and contribute to excess deaths, especially among vulnerable populations such as the elderly, immunocompromised, and those with comorbidities. The lack of effective, broadly applicable antiviral therapies further exacerbates the disease burden, highlighting the urgent need for novel treatment modalities.

Pathophysiology

Severe febrile infections are characterized not only by direct viral cytopathy but also by dysregulated host immune responses. Hallmarks include excessive cytokine release (cytokine storm), endothelial dysfunction, coagulopathy, and multiorgan involvement. Viruses such as influenza and SARS-CoV-2 exploit host cellular machinery for replication, evasion of immune surveillance, and propagation. The interplay between viral virulence factors and host defense mechanisms determines clinical outcomes, with maladaptive responses leading to tissue injury and systemic complications. Understanding these complex host-pathogen interactions is fundamental for the development of host-directed antiviral strategies.

Risk Factors

Risk factors for severe febrile viral infections include advanced age, chronic comorbidities (e.g., cardiovascular disease, diabetes, chronic respiratory conditions), immunosuppression (whether primary or iatrogenic), pregnancy, and genetic predispositions. Socioeconomic factors, such as limited access to healthcare and crowded living conditions, also enhance susceptibility and amplify transmission. Identifying at-risk patient populations is critical for timely intervention and targeted application of emerging host-directed therapies.

Clinical Features

Severe febrile infections typically present with high-grade fever, malaise, headache, myalgia, and progressive systemic symptoms. Complicated cases may evolve to respiratory distress, shock, disseminated intravascular coagulation, encephalopathy, and multiorgan failure. Physical findings often reflect the affected organ systems, with laboratory abnormalities indicating inflammation, cytopenias, and organ dysfunction. Timely recognition of severe manifestations is essential for initiating advanced supportive and investigational therapies.

Diagnosis

Diagnosis of severe febrile viral infections relies on a combination of clinical suspicion, epidemiological context, and laboratory confirmation. Molecular assays (e.g., RT-PCR), serology, and rapid antigen detection tests are commonly utilized for pathogen identification. Biomarkers such as C-reactive protein, procalcitonin, ferritin, and cytokine profiles may assist in disease severity assessment and prognostication. Imaging modalities, including chest radiographs and computed tomography (CT), help evaluate organ involvement and rule out alternative diagnoses. Early and accurate diagnostic workup is pivotal for effective management and patient stratification.

Treatment & Management

Traditional management encompasses supportive care, targeted antiviral therapy (when available), and management of complications such as shock, respiratory failure, and coagulopathy. However, the efficacy of direct-acting antivirals is frequently limited by viral diversity, resistance, and the narrow therapeutic window. Adjunctive therapies such as corticosteroids, immunomodulators, and monoclonal antibodies have been explored with variable success. In this context, host-directed therapies are emerging as promising adjuncts or alternatives, aiming to modulate host pathways critical to viral replication and pathogenesis.

Recent Advances / Emerging Therapies

Host-directed antiviral strategies encompass a diverse array of approaches, including modulation of innate immune responses, targeting cellular entry and trafficking pathways, repurposing of immunomodulatory drugs, and metabolic reprogramming. Agents such as interferons, Janus kinase (JAK) inhibitors, statins, and autophagy modulators have demonstrated potential in preclinical and early-phase clinical studies for various severe viral infections. Notably, baricitinib (a JAK inhibitor) received emergency use authorization for COVID-19, exemplifying the clinical translation of host-targeted approaches. Ongoing trials are evaluating other compounds such as tocilizumab, anakinra, and sphingosine-1-phosphate modulators for their ability to dampen hyperinflammatory responses and improve outcomes. The use of host-directed therapies may also reduce the risk of resistance, offer pan-viral activity, and be combined synergistically with traditional antivirals.

Guideline Recommendations

Current international guidelines increasingly acknowledge the potential role of host-directed therapies, particularly in the management of severe and refractory cases where direct-acting antivirals are ineffective or unavailable. For example, the National Institutes of Health (NIH) and World Health Organization (WHO) guidelines for COVID-19 recommend immunomodulators (e.g., corticosteroids, tocilizumab) in selected patients with severe disease. However, most host-directed interventions remain investigational, and their use should be guided by emerging evidence, patient-specific factors, and multidisciplinary expertise. Clinicians are advised to enroll eligible patients in clinical trials whenever feasible and to monitor for adverse effects associated with immunomodulation.

Conclusion

Host-directed antiviral strategies represent a promising frontier in the management of severe febrile infections, offering potential benefits in terms of efficacy, resistance mitigation, and host-pathogen interaction modulation. Recent advances underscore the importance of a mechanistic understanding of host responses and a precision medicine approach to therapy selection. While several promising agents are under investigation, further high-quality clinical trials are needed to establish safety, efficacy, and optimal integration with existing treatment paradigms. Healthcare professionals should remain abreast of evolving evidence and consider host-directed interventions as part of a comprehensive, individualized management strategy for severe viral infections.